114772-38-2Relevant articles and documents
Synthesis method of 4-bromomethyl-2-methyl formate biphenyl
-
Paragraph 0025; 0031-0032; 0038, (2021/07/14)
The invention discloses a synthesis method of 4-bromomethyl-2-methyl formate biphenyl. The method comprises the following steps: performing bromination reaction in a mode of synchronously dropwise adding bromine and hydrogen peroxide, re-oxidizing hydrobromic acid formed after the reaction into bromine, and performing bromination reaction again, so that the bromine can fully participate in the reaction so as to reduce the use amount of bromine raw materials and improve the yield of the 4-bromomethyl-2-methyl formate biphenyl, waste difficult to treat cannot be generated, hydrogen peroxide is cheap and easy to obtain, and the production cost is remarkably saved.
Synthetic method of 4'-bromomethylbiphenyl-2-carboxylate
-
Paragraph 0058; 0059, (2017/02/02)
The invention discloses a synthetic method of 4'-bromomethylbiphenyl-2-carboxylate. The synthetic method comprises the following steps: 1, hydrolyzing 4'-methyl-2-cyanobiphenyl to obtain 4'-methyl-2-biphenyl formic acid; 2, esterifying 4'-methyl-2-biphenyl formic acid to obtain 4'-methyl-2-biphenyl formate; and 3, reacting 4'-methyl-2-biphenyl formate under the illumination of 15000-20000lx at 20-30DEG C for 4-6h to obtain 4'-bromomethylbiphenyl-2-carboxylate. The synthetic method of 4'-bromomethylbiphenyl-2-carboxylate allows 4'-bromomethylbiphenyl-2-carboxylate to be obtained after hydrolysis, esterification and bromination of 4'-methyl-2-cyanobiphenyl used as an initial material. The route of the method is short, so the problem of raw material waste caused by bromine removal and bromo group introduction is avoided; and a bromination reaction is an illumination reaction, so 4'-bromomethylbiphenyl-2-carboxylate can be directly used in telmisartan synthesis without purifying, thereby the cost is reduced.
New telmisartan-derived PPARγ agonists: Impact of the 3D-binding mode on the pharmacological profile
Obermoser, Victoria,Urban, Margarethe E.,Murgueitio, Manuela S.,Wolber, Gerhard,Kintscher, Ulrich,Gust, Ronald
supporting information, p. 138 - 152 (2016/08/30)
In previous studies, the 4′-((2-propyl-1H-benzo[d]imidazol-1-yl)methyl)-[1,1′-biphenyl]-2-carboxylic acid was identified as pharmacophoric core for PPARγ activation. In this structure-activity relationship study the C2-alkyl chain was elongated and the 2-COOH group was changed to a carbamide/carbonitrile or shifted to the 3- or 4-position. Furthermore, the benzo[d]imidazole was exchanged by 2,3-dihydrobenzo[d]thiazole or 1H-indole. C2-propyl derivatives showed the profile of partial agonists, while elongation of the C2-chain to that of an n-heptyl group or a 4-COOH shift changed the pharmacological profile to that of a potent full agonist. This finding can be explained by binding to the LBD in different ligand conformations. Two anchoring points (Tyr473 and Arg288) exist in the LBD, which have to be contacted to achieve receptor activation. In a crystal violet chemosensitivity assay using COS-7?cells and LNCaP cells expressing PPARγ only the carbamide derivatives influenced the cell growth, independently on the presence of the PPARγ. Therefore, receptor mediated cytotoxicity can be excluded.
Synthesis method of 4'-halogenated methylbiphenyl-2-formic aid alkyl ester
-
, (2016/12/01)
The invention discloses a synthesis method of a 4'-halogenated methylbiphenyl-2-formic acid alkyl ester compound, and belongs to the technical field of organic synthesis. The method includes the following steps that 1, biphenyl-2-formic acid (I) and low alkyl alcohol are subjected to an esterification reaction under an acid catalyst to prepare biphenyl-2-formic acid alkyl ester (II); 2, the temperature in a four-mouth bottle containing biphenyl-2-formic acid alkyl ester (II), paraformaldehyde and a solvent is controlled to be within 20-50 DEG C, zinc halide is added, a dehydrating agent is added drop by drop, liquid chromatography monitoring is performed till the raw materials disappear about 2-5 h later, the reaction is finished, the temperature is lowered to the room temperature, an oil layer is washed, crystallization is performed to prepare 4'-halogenated methylbiphenyl-2-formic acid alkyl ester (III), and recrystallization purification is performed to prepare a pure product of 4'-halogenated methylbiphenyl-2-formic acid alkyl ester (III). According to the method, with biphenyl-2-formic acid as the starting raw material, the sartan drug intermediate 4'-halogenated methylbiphenyl-2-formic acid alkyl ester is prepared; the process is simple, conditions are easy to control, the raw materials are cheap and easy to get, production cost is low, environmental pollution is small, and the method is suitable for industrial production.
Synthesis of new biphenyl-substituted quinoline derivatives, preliminary screening and docking studies
Shashikumar, Nellisara D,Krishnamurthy, Ganganaika,BhojyaNaik, Halehatti S,Lokesh, Mayasandra R,Jithendrakumara, Kaginalli S
, p. 205 - 212 (2016/03/01)
New quinoline derivatives containing biphenyl ring were synthesized and characterized by IR, 1H NMR and mass spectral studies. The synthesized compounds were screened for antimicrobial, anthelmintic activities as well as free radical scavenging property against the DPPH radical. The minimum inhibition concentration values showed promising inhibiting activity and are potent biological agents. The compounds showed minimum binding energy towards β-tubulin. The compounds 11a, 11c, 13c and 13d have good affinity towards the active pocket and may be considered as a good inhibitor of β-tubulin.
Synthesis of new biphenyl-substituted quinoline derivatives, preliminary screening and docking studies
Shashikumar, Nellisara D.,Krishnamurthy, Ganganaika,Bhojyanaik, Halehatti S.,Lokesh, Mayasandra R.,Jithendrakumara, Kaginalli S.
, p. 205 - 212 (2014/04/03)
New quinoline derivatives containing biphenyl ring were synthesized and characterized by IR, 1H NMR and mass spectral studies. The synthesized compounds were screened for antimicrobial, anthelmintic activities as well as free radical scavenging property against the DPPH radical. The minimum inhibition concentration values showed promising inhibiting activity and are potent biological agents. The compounds showed minimum binding energy towards ?-tubulin. The compounds 11a, 11c, 13c and 13d have good affinity towards the active pocket and may be considered as a good inhibitor of β-tubulin. Indian Academy of Sciences.
Synthesis and evaluation of quinazoline derivatives as phosphodiesterase 7 inhibitors
Sánchez, Ana I.,Martínez-Barrasa, Valentín,Burgos, Carolina,Vaquero, Juan J.,Alvarez-Builla, Julio,Terricabras, Emma,Segarra, Víctor
, p. 2370 - 2378 (2013/05/09)
The latest scientific findings concerning PDE7 and PDE4 inhibition suggest that selective small-molecule inhibitors of both enzymes could provide a novel approach to treat a variety of immunological diseases. In this context, we describe a new series of quinazoline derivatives from quinazolin-4-thiones which include a substituted biphenyl fragment. Some of these compounds show inhibitory potencies at sub-micromolar levels against the catalytic domain of PDE7.
1-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl} -pyrrolidine-2-carboxamide: Investigation of structural variations
Catalano, Alessia,Carocci, Alessia,Di Mola, Antonia,Bruno, Claudio,Vanderheyden, Patrick M. L.,Franchini, Carlo
scheme or table, p. 617 - 626 (2012/06/29)
We recently reported a series of 1-acyl-N-(biphenyl-4-ylmethyl)pyrrolidine- 2-carboxamides as AT1 receptor ligands. The most potent compound of the series, 1-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}- pyrrolidine-2-carboxamide, showed an interesting affinity for the receptor. To investigate the influence of structure variations on affinity, the synthesis of additional compounds belonging to this series has been performed. Biological tests run on the newly synthesized compounds on CHO-hAT1 cells stably expressing the human AT1 receptor confirm our previous hypothesis, i.e. that, within this series, the length of the acyl chain, the substitution of the amidic group and the nature of the acidic one are crucial for the receptor interaction, being a valeric chain, a secondary amidic function and the tetrazole moiety, respectively, the optimal ones. New 1-acyl-N-(biphenyl-4- ylmethyl)pyrrolidine-2-carboxamides have been designed by enlarging our previously reported series in order to clarify the requirements for AT 1 receptor interaction. Copyright
NOVEL BLT2-MEDIATED DISEASE, AND BLT2 BINDING AGENT AND COMPOUND
-
Page/Page column 35, (2010/11/25)
[PROBLEM] The compound that selectively binds to BLT2 and the preventive and/or therapeutic drug for BLT2-mediated disease such as skin disease are needed. [MEANS FOR SOLVING THE PROBLEMS] The present invention provides the compound with BLT2 binding activity, salt thereof, solvate thereof or prodrug thereof. Since the compound with BLT2 binding activity, particularly the compound represented by the formula (I) , salt thereof, solvate thereof or prodrug thereof (symbols in formula have the same meanings as specification.) have BLT2 binding activity, it is useful for prevention and/or therapy of BLT2 mediated diseases, e.g., dermatosis, intestinal disease, HIV infection, acquired immunodeficiency syndrome, rejection to transplant, transplant rejection, graft-versus-host disease, autoimmune disease, allergic disease, inflammation, infection, ulcers, lymphoma, malignant tumor, leucaemia, arterial sclerosis, hepatitis, hepatic cirrhosis or cancer, etc.
An efficient and impurity-free process for telmisartan: An antihypertensive drug
Reddy, Kikkuru Srirami,Srinivasan, Neti,Reddy, Chinta Raveendra,Kolla, Naveenkumar,Anjaneyulu, Yerremilli,Venkatraman, Sundaram,Bhattacharya, Apurba,Mathad, Vijayavitthal T.
, p. 81 - 85 (2012/12/26)
Telmisartan (1), a substituted dibenzimidazole derivative, is an antihypertensive drug, essentially used to control blood pressure. An improved, cost-effective, and impurity-free process for telmisartan (1) suitable for large-scale production is described here by addressing various process development issues. The overall yield obtained from this newly developed process is around 50% (over five steps) compared to the literature reported process (21%, over eight steps).
